PK parameters= Cmax; Tmax; F: bioavailability; t1/2: half-life; VD: volume of distribution; Cl: clearance; PPB: plasma protein binding;(EQN means that value was calculated using VD=(Cl*t1/2)/0.693)
Primary Target and PDB code of Protein-Drug complex
IMMUNOSUPPRESSANTS TREATMENT OF TREATMENT OF PATIENTS WITH RELAPSING FORMS OF MULTIPLE SCLEROSIS ACTIVATES THE NUCLEAR FACTOR (ERYTHROID-DERIVED 2)-LIKE 2 (NRF2) PATHWAY METABOLITE MONOMETHYL FUMARATE IS A NICOTINIC ACID RECEPTOR AGONIST
ORAL
SOLUBILITY HIGHLY SOLUBLE IN WATER
NICOTINIC ACID RECEPTOR (NIACR)
PDB6LRZ (CRYSTAL STRUCTURE OF KEAP1 IN COMPLEX WITH DIMETHYL FUMARATE (DMF))
PK parameters= Cmax; Tmax; F: bioavailability; t1/2: half-life; VD: volume of distribution; Cl: clearance; PPB: plasma protein binding;(EQN means that value was calculated using VD=(Cl*t1/2)/0.693)
Primary Target and PDB code of Protein-Drug complex
IMMUNOSUPPRESSANTS TREATMENT OF TREATMENT OF PATIENTS WITH RELAPSING FORMS OF MULTIPLE SCLEROSIS ACTIVATES THE NUCLEAR FACTOR (ERYTHROID-DERIVED 2)-LIKE 2 (NRF2) PATHWAY NICOTINIC ACID RECEPTOR AGONIST
ORAL
Cmax 12.9 MICROMOLAR
Tmax 2.25 HOUR
VD 63 LITER
PPB 36 PERCENT
Cl 43.6 LITER / HOUR (EQN)
HT 1 HOUR
NICOTINIC ACID RECEPTOR (NIACR)
PDB8JHN (STRUCTURE OF MMF-GPR109A-G PROTEIN COMPLEX)